Reduced queues for drug certification and analysis time for rare disease treatments are among the major breakthroughs.

Reduction of the queues for drug certification and the time of analysis for treatments of rare diseases, and increased import of products destined for research are among the main advances of Anvisa in 2017 presented by the CEO Jarbas Barbosa. He attended the Social Affairs Committee (CAS), chaired by Senator Marta Suplicy (MDB-SP), on Wednesday (4) to detail the Agency’s Activities Report 2017.

For more information go to